权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Structure-based Vaccine Design for CCHFV

基于结构的 CCHFV 疫苗设计

基本信息

批准号：
10405068
负责人：
Kartik Chandran
金额：
$ 42.85万
依托单位：
UNIVERSITY OF TEXAS AT AUSTIN
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-06-25 至 2025-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10405068
关键词：
Acute Africa Animal Model Antibodies Antibody Response Antibody Therapy Antigens Case Fatality Rates Categories Category A pathogen Cells Central Asia Chimeric Proteins Complex Coronavirus Crimean Hemorrhagic Fever Crimean-Congo Hemorrhagic Fever Virus Crystallization Data Data Protection Disease Disease Outbreaks Dyes Engineering Epitope Mapping Epitopes Evaluation Family Filovirus Funding Genome Geographic Locations Glycoproteins Goals Human IFNAR1 gene Immune response Immunocompromised Host Immunologics Incidence International Laboratories Laboratory Animal Models Life Livestock Maps Membrane Fusion Middle East Molecular Monoclonal Antibodies Morbidity - disease rate Mucins Mus Nairovirus National Institute of Allergy and Infectious Disease Pathogenesis Patients Process Proteins Public Health RNA Viruses Reagent Respiratory syncytial virus Sampling Site Southern Europe Structure Subunit Vaccines Technology Therapeutic antibodies Tick-Borne Diseases Ticks Vaccine Antigen Vaccine Design Vaccines Viral Viral Envelope Proteins Viral Genome Viral Hemorrhagic Fevers Virus Virus Diseases Western Asia Work base clinical development cross reactivity design disorder prevention experience global temperature immunogenicity in vivo insight interest lead candidate medical countermeasure migratory bird mortality mouse model nanoparticle neutralizing antibody novel novel vaccines prevent structural glycoprotein tick-borne tick-borne pathogen tool type I interferon receptor vaccine candidate vaccine development vector

项目摘要

Project Summary/Abstract Crimean-Congo hemorrhagic fever virus (CCHFV) causes a life-threatening tick-borne disease in humans. The disease presents as a severe form of hemorrhagic fever with a case fatality rate of 10–40%. CCHFV outbreaks have spanned a wide geographic area ranging from Western and Central Asia, the Middle East, Africa and Southern Europe. Increasing global temperatures, migratory birds, and the international livestock trade have all potentially contributed toward the spread of Hyalomma ticks—the primary vector for CCHFV. Expanding endemic zones, widespread morbidity and significant mortality make CCHFV an acute threat to public health and thus is listed as a NIAID Category A priority pathogen. The viral genome encodes a glycoprotein precursor that is processed into two structural glycoproteins—Gn and Gc—and two secreted glycoproteins—a mucin-like domain and GP38. Protective antibodies have been isolated that target Gc or GP38, suggesting that these two proteins should be given priority for vaccine development. Here we propose to engineer Gc- and GP38-based immunogens that focus the immune response onto broadly conserved epitopes that are capable of eliciting protective antibody responses. To accomplish our goal, we will structurally characterize CCHFV glycoproteins and their interactions with human-derived antibodies, rationally engineer vaccine antigens based in part on the structural information, and characterize the immune responses elicited by these antigens in animal models. These results will be used to guide further improvements of the immunogens, including display on self-assembling multi-valent nanoparticles, and the most promising candidates will be evaluated in a lethal murine model of CCHFV challenge. Given our expertise, unique reagents, and preliminary data, we are confident that we can deliver a state-of-the-art subunit vaccine candidate with the potential to induce cross-reactive protective antibodies, thereby satisfying an unmet need against this NIAID Category A tick-borne pathogen.

项目总结/摘要克里米亚-刚果出血热病毒（CCHFV）在人类中引起威胁生命的蜱传疾病。该病表现为严重的出血热，病死率为10- 40%。CCHFV 疫情跨越了广泛的地理区域，从西亚和中亚，中东，非洲和南欧。全球气温上升，候鸟和国际牲畜贸易都有可能促进CCHFV的主要媒介--璃眼蜱的传播。不断扩大的流行区、广泛的发病率和显著的死亡率使CCHFV成为严重威胁，公共卫生，因此被列为NIAID A类优先病原体。病毒基因组编码一种一种糖蛋白前体，被加工成两种结构糖蛋白-Gn和GC-以及两种分泌糖蛋白糖蛋白-粘蛋白样结构域和GP 38。已经分离出靶向Gc或Gc的保护性抗体。 GP 38，这表明这两种蛋白质应优先用于疫苗开发。这里我们我建议设计基于GC和GP 38的免疫原，将免疫反应集中在广泛的能够引发保护性抗体应答的保守表位。为了实现我们的目标，我们将在结构上表征CCHFV糖蛋白及其与人源抗体的相互作用，部分基于结构信息合理地工程化疫苗抗原，并表征在动物模型中由这些抗原引起的免疫应答。这些结果将用于指导进一步的免疫原的改进，包括在自组装多价纳米颗粒上的展示，以及将在CCHFV攻击的致死鼠模型中评价最有希望的候选物。鉴于我们专业知识，独特的试剂和初步的数据，我们有信心，我们可以提供一个国家的最先进的亚单位候选疫苗有可能诱导交叉反应性保护性抗体，从而满足了针对这种NIAID A类蜱传病原体的未满足的需求。